In summary, OIP5-AS1, as a ceRNA, could promote the progression of pancreatic cancer by targeting miR-186-5p/NGFR and affecting the prognosis of patients, findings that might be related to the action of proNGF. This evidence concerns the gene OIP5 and pancreatic neoplasm.